Hannah Smith, NP
Adult Health · Mobile, ALNPI 1386068708
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.1% of the total across 184 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations.
Across 184 payments — averaging $23.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$715
- Sumitomo Pharma America, Inc.$484
- Astellas Pharma US Inc$411
- Dermavant Sciences, Inc.$324
- Endo Pharmaceuticals Inc.$296
- Dendreon Pharmaceuticals LLC$241
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,12794%
- Education$2586%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 25 | $715 |
| Sumitomo Pharma America, Inc. | 26 | $484 |
| Astellas Pharma US Inc | 18 | $411 |
| Dermavant Sciences, Inc. | 3 | $324 |
| Endo Pharmaceuticals Inc. | 13 | $296 |
| Dendreon Pharmaceuticals LLC | 5 | $241 |
| Amgen | 10 | $205 |
| Endo USA, Inc. | 6 | $147 |
| Axonics, Inc. | 3 | $145 |
| Urogen Pharma, Inc. | 8 | $140 |
| Antares Pharma, Inc. | 4 | $127 |
| Pfizer | 7 | $126 |
| Myovant Sciences Inc. | 8 | $117 |
| Coloplast | 6 | $86 |
| 180 Medical, Inc. | 3 | $77 |
| Urovant Sciences Inc | 3 | $53 |
| Procept Biorobotics Corporation | 1 | $53 |
| AbbVie | 2 | $48 |
| Merck | 2 | $47 |
| Blue Earth Diagnostics | 2 | $47 |
| Laborie Medical Technologies Corp. | 3 | $45 |
| Verity Pharmaceuticals Inc. | 3 | $44 |
| ABC Home Medical Supply, Inc. | 2 | $44 |
| Ferring Pharmaceuticals Inc. | 2 | $42 |
| Bayer | 2 | $34 |
| Tolmar, Inc. | 2 | $33 |
| Novartis | 2 | $33 |
| AstraZeneca | 2 | $31 |
| Clarus Therapeutics Inc. | 3 | $30 |
| Immunitybio, Inc. | 1 | $28 |
| Hollister Incorporated | 1 | $26 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
| Avyxa Pharma, LLC | 1 | $20 |
| Mission Pharmacal Company | 1 | $18 |
| Accord Healthcare, Inc. | 1 | $16 |
| Progenics Pharmaceuticals, Inc. | 1 | $16 |
| Tolmar Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VTAMA$239
- Erleada$138
- AKEEGA$138
- Axonics r-SNM System$116
- PROVENGE$109
How this compares
$4,385 in reported general payments places this provider in the 85th percentile of 308 adult health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 233 | $154,840 |
| MyrbetriqMirabegron | 80 | $47,943 |
| Methenamine Hippurate | 166 | $11,009 |
| Tamsulosin Hcl | 321 | $4,311 |
| Cefdinir | 269 | $3,952 |
| Bethanechol Chloride | 36 | $2,658 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 11 | $2,560 |
| Oxybutynin Chloride ErOxybutynin Chloride | 80 | $1,704 |
| Oxybutynin Chloride | 93 | $1,602 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $1,317 |
| Solifenacin Succinate | 14 | $1,169 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 40 | $1,139 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 64 | $1,108 |
| Cephalexin | 86 | $903 |
| Testosterone Cypionate | 20 | $861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $484 | $154,840233 claims |
| Astellas Pharma US IncMyrbetriq | $411 | $47,94380 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 adult health providers in Alabama.
Other adult health in Mobile
- Virginia RudolfMobile$6K
- Mary SmithMobile$4K
- Vanessa JonesMobile$4K
- Wendy CantrellMountain Brk$276K
- Lanier OhareBirmingham$42K
- Jessica WrightBirmingham$33K
- Sara HopperBirmingham$21K
- Andrea SuttonBirmingham$21K
- Olivia ViseHoover$15K
- Lindsay SmithPelham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.